Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
- Resource Type
- Article
- Authors
- Hussain, M. Junaid; Robinson, Myra M.; Hamadeh, Issam; Arnall, Justin; Bhutani, Manisha; Atrash, Shebli; Friend, Reed; Pineda‐Roman, Mauricio; Symanowski, James T.; Usmani, Saad Z.; Voorhees, Peter M.
- Source
- British Journal of Haematology. Jul2019, Vol. 186 Issue 1, p140-144. 5p. 1 Chart, 1 Graph.
- Subject
- *MULTIPLE myeloma
*THALIDOMIDE
*BORTEZOMIB
*T helper cells
*CYTOTOXIC T cells
*KILLER cells
- Language
- ISSN
- 0007-1048
The article focuses on the role of Daratumumab, pomalidomide and dexamethasone (Pd) combination therapy for the treatment of relapsed and refractory multiple myeloma. It mentions the addition of daratumumab to the Pd backbone (DaraPd) for the patients with relapsed and refractory multiple myelom and also discussions on daratumumab that depletes levels of CD38 (cluster of differentiation 38).